Pontifax Management 4 GP (2015) Ltd. 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-18 5:10 pm Purchase |
2025-04-17 | 13D | Keros Therapeutics, Inc. KROS |
Pontifax Management 4 GP (2015) Ltd. | 4,787,331 11.800% |
52,824 (+1.12%) |
Filing |